...
首页> 外文期刊>Peritoneal dialysis international: Journal of the International Society for Peritoneal Dialysis >Towards standardized reporting in studies of encapsulating peritoneal sclerosis
【24h】

Towards standardized reporting in studies of encapsulating peritoneal sclerosis

机译:在封装性腹膜硬化研究中实现标准化报告

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Encapsulating peritoneal sclerosis (EPS), a serious but uncommon complication of peritoneal dialysis (PD), initially well described in the Japanese patient population (1-3), is now widely recognized. Because of the severe morbidity and mortality attached, EPS has the potentialto negatively affect perceptions of the value of PD as a long-term therapy and so affect the take-on rate and increase early transfer to HD. It is now well established that EPS is strongly associated with duration of PD therapy (4,5), with ultrafiltration failure associated with membrane fibrosis (6,7), and also, paradoxically, with stopping PD. Nevertheless, significant deficits in the understanding of EPS remain. That lack of understanding is implicit in nonspecific diagnostic criteria and an uncertain association with peritonitis, issues that arise in a study by Wong et at. (8) in this issue of Peritoneal Dialysis International.
机译:封装性腹膜硬化症(EPS)是一种严重但不常见的腹膜透析(PD)并发症,最初在日本患者人群(1-3)中得到了很好的描述,如今已得到广泛认可。由于严重的发病率和死亡率,EPS可能会对PD作为长期疗法的价值产生负面影响,从而影响摄取率并增加早期向HD的转移。现在已经确定EPS与PD治疗的持续时间密切相关(4,5),与膜纤维化相关的超滤失败(6,7),以及与PD停止有关的矛盾。但是,在对EPS的理解上仍然存在大量缺陷。缺乏了解隐含在非特异性诊断标准中以及与腹膜炎的不确定关联,这是Wong等人在一项研究中出现的问题。 (8)本期《腹膜透析国际》。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号